Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Real-world, Longitudinal Observational Study of the Impact of Tildrakizumab on Patient Reported Outcomes in Patients With Moderate-to-severe Psoriasis in Canada

NCT07370766 is registered in ClinicalTrials.gov with Chronicle Academy as lead sponsor.

NCT NCT07370766
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07370766 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Real-world, Longitudinal Observational Study of the Impact of Tildrakizumab on Patient Reported Outcomes in Patients With Moderate-to-severe Psoriasis in Canada
Lead sponsor
Chronicle Academy
Phase
Observational
Overall status
Recruiting
Start date
November 25, 2025
Completion date
May 30, 2027
Enrollment
80 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe psoriasis, psoriasis (pso)